V Wealth Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

V Wealth Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-500	Closed	-$14K	–	195
2017 Q2	$14K	Buy	+500	New	+$14.9K	0.01%	503

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

V Wealth Advisors's ACAD Position: Q3 2017 in Review

V Wealth Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q3 2017, closing a stake of 500 shares — an estimated $14K sold.

V Wealth Advisors first reported a position in ACAD in Q2 2017 and held it in 1 quarter. The position peaked at $14K in Q2 2017. 212 funds tracked by Wall St. Rank hold ACAD as of Q3 2017.

V Wealth Advisors reported no remaining Acadia Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
V Wealth Advisors sold 500 Acadia Pharmaceuticals shares in Q3 2017, an estimated $14K.
V Wealth Advisors first reported a position in Acadia Pharmaceuticals in Q2 2017 and held it in 1 quarter.
V Wealth Advisors's Acadia Pharmaceuticals position peaked at $14K in Q2 2017.
212 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2017.

Based on V Wealth Advisors's 13F filing for Q3 2017, filed 12 Oct 2017.